Related Experiment Videos
Chimeric antigen receptor T cells: a novel therapy for solid tumors.
Shengnan Yu1, Anping Li2, Qian Liu1
1Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Journal of Hematology & Oncology
|March 31, 2017
Summary
Chimeric antigen receptor T (CAR-T) cell therapy offers a novel adoptive antitumor treatment. This review explores CAR-T cell progress targeting EGFR, HER2, and MSLN, highlighting challenges and advancements in cancer therapy.
Area of Science:
- Oncology
- Immunotherapy
- Cell Therapy
Background:
- Chimeric antigen receptor T (CAR-T) cell therapy is an emerging adoptive immunotherapy.
- CAR-T cells target tumor-associated antigens (TAAs) on cancer cells.
- EGFRvIII is an example of a TAA targeted by CAR-T cells.
Purpose of the Study:
- To review the preclinical and clinical advancements of CAR-T cell therapy.
- To summarize CAR-T cell targeting of EGFR, HER2, and MSLN.
- To discuss current challenges in CAR-T cell therapy.
Main Methods:
- Review of preclinical studies on CAR-T cell therapy.
- Analysis of clinical trial data for CAR-T cell efficacy.
- Examination of CAR structure modifications for enhanced cytotoxicity.
Main Results:
- CAR-T cell therapy shows breakthroughs in hematological malignancies.
- Promising outcomes observed in solid tumors through clinical trials.
- Third-generation CAR-T cells exhibit enhanced antitumor activity and persistence.
Conclusions:
- CAR-T cell therapy holds significant potential for cancer treatment.
- Targeting specific TAAs like EGFR, HER2, and MSLN is crucial.
- Overcoming challenges is key to expanding CAR-T cell therapy applications.